Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 3Genitourinary 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Prostatic Neoplasms 291Carcinoma, Renal Cell 172Kidney Neoplasms 118Urinary Bladder Neoplasms 102Breast Neoplasms 70Neoplasms 64Melanoma 48Testicular Neoplasms 45Sarcoma 45Wilms Tumor 44Lung Neoplasms 42Ovarian Neoplasms 41Neuroblastoma 39Colonic Neoplasms 34Lymphoma, Non-Hodgkin 32Lymphoma 31Osteosarcoma 28Neoplasm Metastasis 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Uterine Cervical Neoplasms 24Colorectal Neoplasms 23Carcinoma, Transitional Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Medulloblastoma 22Urethral Neoplasms 21Central Nervous System Neoplasms 21Carcinoma, Ovarian Epithelial 21Burkitt Lymphoma 21

Interventions

ixabepilone 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Sarcoma, Synovial × Genitourinary × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

NCT00331643 2014-11-14

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡